72 results
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
.
Stockholder Meetings
Our bylaws provide that a special meeting of stockholders may be called only by our chairperson of the board, chief executive officer
424B5
9hfq2m9xl ki1
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
kbzx0 zxzzz7g
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
8owxep8k jv5hl
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
eh15ww
11 Mar 21
Prospectus supplement for primary offering
9:19am
424B4
vw0nmzcp7o
17 Feb 21
Prospectus supplement with pricing info
7:14am
8-K
u6lnrb
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-3.3
d9xz44
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-10.8
0u2sf2txi3x9 xo
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
xn6aftop9t9wufc3oh
3 Nov 20
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
6:06am
8-K
EX-99.1
40felgj1jkh5hha
3 Nov 20
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
6:06am
425
6ho5go
3 Nov 20
Business combination disclosure
6:04am